ADMA Biologics

- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 624
- Market Cap
- $4B
- Website
- http://www.admabiologics.com
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
3
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)
- Conditions
- Primary Immune Deficiency
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05070455
- Locations
- 🇺🇸
Immunoe Research Centers, Centennial, Colorado, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16
- Conditions
- Humoral Immune Response
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03164967
- Locations
- 🇺🇸
IMMUNOe Research Centers, Centennial, Colorado, United States
🇺🇸Duke University Medical Center, Durham, Florida, United States
🇺🇸Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States
A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
- Conditions
- Primary Immune Deficiency Disorder
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03037359
- Locations
- 🇺🇸
Santa Barbara Specialty Pharmacy, Carpinteria, California, United States
🇺🇸Allergy and Asthma of the Bay Area, Walnut Creek, California, United States
🇺🇸Immunoe Research Centers, Centennial, Colorado, United States
Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
- Conditions
- Primary Immune Deficiency Disorder
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT01814800
- Locations
- 🇺🇸
IMMUNOe Health Centers, Cenntennial, Colorado, United States
🇺🇸Allergy Associates of the Palm Beaches, P.A., North Palm Beach, Florida, United States
🇺🇸Family Allergy Center, PC, Atlanta, Georgia, United States
RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
- Conditions
- Upper Respiratory Tract InfectionLower Respiratory Tract Infection
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00632463
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
- Prev
- 1
- 2
- Next
News
ADMA Biologics Secures FDA Clearance for Yield Enhancement Process, Poised for Margin Expansion in 2026
ADMA Biologics has received FDA clearance for a yield enhancement process that is expected to significantly improve production margins for its immunoglobulin products starting in 2026.
FDA Approves ADMA Biologics' Innovative Yield Enhancement Process for Immune Globulin Production
ADMA Biologics has received FDA approval for a groundbreaking production process that increases immune globulin yields by approximately 20% from the same plasma volume, becoming the first U.S. company to achieve this regulatory milestone.